Astle Christopher's Form 4/A amendment
AmendedZymeworks Inc.ZYME · filed Dec 23, 2022
- Accession no.
- 0000899243-22-039332
- Filed
- Dec 23, 2022
- Trade date
- Dec 12, 2022
- Filing delay
- 11 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Dec 14, 2022
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $5.33K. It was filed 11 days after the trade.
This amendment replaces 0000899243-22-038516 (filed Dec 14, 2022).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Astle ChristopherCIK 0001915257 | Officer (SVP & Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 12, 2022 | Common Stock | MOption exerciseAcquired | +1,550 | $0.00 | $0 | 2,220 | Direct | |
| Dec 12, 2022 | Common Stock | SSaleDisposed | −887 | $6.01F3 | −$5,330.87 | 1,333 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 12, 2022 | Common Shares | MOption exerciseDisposed | −1,550 | $0.00 | $0 | 1,550 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents shares of common stock issued upon vesting of one half of the restricted stock units ("RSUs") granted on December 10, 2021.
- F2
Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.99 to $6.035, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
- F5
The RSUs were granted on December 10, 2021 and vest in two equal annual instalments beginning on December 12, 2022.
Remarks
This Amendment is being filed soley to include Exhibit 24 - Power of Attorney, which was inadvertently omitted in the Form 4 filed December 14, 2022. Exhibit List - Exhibit 24 - Power of Attorney. On October 13, 2022, the Issuer (formerly Zymeworks Delaware Inc., a Delaware corporation) became the successor issuer of Zymeworks BC Inc. (formerly Zymeworks Inc., a corporation continued under the Business Corporations Act (British Columbia)) pursuant to Rule 12g-3 of the Securities Exchange Act of 1934, as amended. On such date the Issuer completed a series of transactions, including a redomicile, pursuant to a statutory plan of arrangement under Section 288 of the Business Corporations Act (British Columbia), as a result of which common shares of Zymeworks BC Inc. were exchanged for either shares of common stock of the Issuer or exchangeable shares issued by Zymeworks ExchangeCo Ltd., an indirect subsidiary of the Issuer.